Kimberly-Clark is buying Tylenol maker Kenvue in an approximately $48.7 billion cash-and-stock deal, creating a massive consumer health goods company.

This comes about a month after President Donald Trump claimed that taking Tylenol during pregnancy could increase the risk of autism in children, despite no conclusive evidence linking the drug to the condition.

More than 3,000 bottles of the popular pain reliever have been pulled from shelves over a packaging defect. The FDA has given the recall the second-highest risk level.